Anzeige
Meldung des Tages: Gold über 5.000 USD verändert die Wirtschaftlichkeit grundlegend!

Novavax Aktie News

Aktie
WKN:  A2PKMZ ISIN:  US6700024010 US-Symbol:  NVAX Branche:  Biotechnologie Land:  USA
9,63 $
+0,46 $
+5,02%
8,1010 € 26.01.26
Depot/Watchlist
Marktkapitalisierung *
942,83 Mio. €
Streubesitz
29,59%
KGV
3,13
neu: Nachhaltigkeits-Score
19 %
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 6,37: JZ6XPT
Werbung

Novavax News

20.01.26 - PR Newswire
Novavax Announces Entering into a License Agreement with Pfizer
Novavax Announces Entering into a License Agreement with Pfizer PR Newswire
07.01.26 - PR Newswire
Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
12.11.25 - PR Newswire
Novavax to Participate in Jefferies London Healthcare Conference
Novavax to Participate in Jefferies London Healthcare Conference PR Newswire
06.11.25 - PR Newswire
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights PR Newswire
04.11.25 - PR Newswire
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment PR Newswire
30.10.25 - PR Newswire
Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025
Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025 PR Newswire
22.10.25 - PR Newswire
Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy
Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy PR Newswire
07.10.25 - PR Newswire
Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment PR Newswire
30.09.25 - PR Newswire
Novavax Announces Progress on Sanofi Agreement
Novavax Announces Progress on Sanofi Agreement PR Newswire
04.09.25 - PR Newswire
Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment
Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment PR Newswire
03.09.25 - PR Newswire
Novavax to Participate in the Cantor Global Healthcare Conference
Novavax to Participate in the Cantor Global Healthcare Conference PR Newswire
27.08.25 - PR Newswire
Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S. PR Newswire
22.08.25 - wallstreetONLINE Redaktion
Milliarden-Verlustgefahr: Nach zweistelligem Absturz: Warum Novavax-Investoren weiter zittern müssen
Novavax steht unter massivem Druck: Ein Analysten-​Downgrade, neue Milliarden-​Schulden und Zweifel an der Impfstoff-​Zukunft haben die Aktie zweistellig abstürzen lassen. ...
21.08.25 - PR Newswire
Novavax Announces Convertible Debt Refinancing
Novavax Announces Convertible Debt Refinancing PR Newswire
06.08.25 - PR Newswire
Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights
Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights PR Newswire
30.07.25 - PR Newswire
Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025
Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025 PR Newswire
24.07.25 - PR Newswire
Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study PR Newswire
11.06.25 - PR Newswire
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial
Novavax's COVID-19-Influenza Combination and Stand-​alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a ...
29.05.25 - PR Newswire
Novavax to Participate in Upcoming Investor Conferences
Novavax to Participate in Upcoming Investor Conferences PR Newswire
19.05.25 - wallstreetONLINE Redaktion
+15 Prozent am Montag: Novavax zündet den Kursturbo: Ist DAS die Chance auf eine Trendwende?
Die Aktie von Novavax geht am Montag durch die Decke und legt deutlich zweistellig zu. Grund hierfür sind gute Nachrichten vom zurückliegenden Wochenende.Auf dem Höhepunkt ...

Newssuche

Videos

newspaper
01:40 Uhr +0,18%
Wahnsinn! Warum Daytrader im FDAX oft verlieren
Ab Montag, dem 2. Februar börsentäglich ab 18 Uhr - FEIERABEND-​TRADING! Echte Trades auf Basis ... Mehr »